Physician profile
Stephan P Babirak
NPI 1689619884
$802,275.08
in general payments reported to CMS, 2019-2025
54 companies · $75K in 2025
The $75K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161K · 2020: $97K · 2021: $138K · 2022: $138K · 2023: $94K · 2024: $100K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $212K · Travel and Lodging: $33K · Food and Beverage: $14K · Consulting Fee: $5,836 · Honoraria: $2,450 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $212,169.00 |
| Travel and Lodging | $33,300.86 |
| Food and Beverage | $14,416.01 |
| Consulting Fee | $5,836.00 |
| Honoraria | $2,450.00 |
| Education | $377.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $258,754.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $240,619.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78,919.58 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Kaneka Medical America LLC | $55,417.00 | 2020-2021 | |
| Abbvie INC. | $35,812.62 | 2019-2025 | Synthroid |
| Amgen INC. | $27,884.16 | 2019-2025 | Repatha, Evenity, Tepezza |
| Esperion Therapeutics, INC. | $21,951.54 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $17,626.68 | 2019-2025 | Evkeeza |
| Abbott Laboratories | $15,025.21 | 2019-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $14,100.27 | 2019-2024 | Xarelto |
| Regeneron Pharmaceuticals, INC. | $9,424.69 | 2019-2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $9,178.08 | 2019-2024 | |
| Madrigal Pharmaceuticals | $4,034.63 | 2024-2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $2,401.29 | 2021-2025 | |
| Medtronic, INC. | $2,232.96 | 2021-2024 | Minimed 780g, Minimed 770g, Guardian Connect |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,538.93 | 2019-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $1,100.49 | 2021-2025 | |
| Corcept Therapeutics | $752.84 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $717.07 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amarin Pharma, INC. | $683.94 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $549.66 | 2021-2023 | Xarelto |
| Ionis Pharmaceuticals, INC. | $427.07 | 2025 | Tryngolza |
| Merck Sharp & Dohme LLC | $344.18 | 2019-2022 | |
| Pfizer INC. | $322.39 | 2019-2024 | |
| Medtronic Minimed, INC. | $248.09 | 2019-2020 | |
| Sequel Med Tech, LLC | $238.05 | 2025 | Twiist |
| Antares Pharma, INC. | $231.41 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Amryt Pharma Holdings Ltd | $174.03 | 2020-2023 | Mycapssa |
| Dexcom, INC. | $163.26 | 2021-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $154.49 | 2019-2022 | |
| Echosens North America, INC. | $140.73 | 2024 | Fibroscan |
| Ascendis Pharma Endocrinology INC | $104.50 | 2023-2025 | Yorvipath |
| Chiesi USA, INC. | $98.06 | 2024-2025 | Juxtapid, Mycapssa, Ferriprox |
| Recordati_rare_diseases_inc. | $80.59 | 2021-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $79.81 | 2022-2025 | Cequr Simplicity |
| Horizon Therapeutics Plc | $75.35 | 2021-2023 | Tepezza |
| Ipsen Biopharmaceuticals, INC | $66.95 | 2020-2022 | |
| Tolmar, INC. | $64.04 | 2023-2024 | |
| Halozyme INC | $60.78 | 2023 | |
| Kyowa Kirin, INC. | $59.47 | 2023-2024 | Crysvita |
| Endo Pharmaceuticals INC. | $56.04 | 2021 | |
| Medicure Pharma INC. | $50.85 | 2021 | |
| Tandem Diabetes Care, INC. | $44.89 | 2022 | |
| Akcea Therapeutics, INC. | $43.66 | 2021 | |
| Lifescan, INC. | $41.61 | 2019-2020 | |
| Becton, Dickinson and Company | $26.38 | 2021 | |
| Grt US Holding, INC. | $24.68 | 2022 | |
| Mannkind Corporation | $24.43 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.92 | 2024 | Vpriv |
| Lexicon Pharmaceuticals, INC. | $22.67 | 2023 | Inpefa |
| Neurocrine Biosciences, INC. | $17.85 | 2025 | |
| Bigfoot Biomedical INC | $14.03 | 2021 | |
| Gilead Sciences, INC. | $13.81 | 2019 | |
| Eusa Pharma (US) LLC | $12.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Babirak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.